Abraham Tsur1, Flora Kalish1, Jordan Burgess1, Nihar R Nayak2, Hui Zhao1, Kerriann M Casey3, Maurice L Druzin4, Ronald J Wong5, David K Stevenson1. 1. Dept of Pediatrics, Division of Neonatal and Developmental Medicine, Stanford University School of Medicine, Stanford, CA, USA. 2. Dept of Obstetrics & Gynecology, Wayne State University, Detroit, MI, USA. 3. Dept of Comparative Medicine, Stanford University School of Medicine, Stanford, CA, USA. 4. Dept of Obstetrics & Gynecology, Stanford University School of Medicine, Stanford, CA, USA. 5. Dept of Pediatrics, Division of Neonatal and Developmental Medicine, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: rjwong@stanford.edu.
Abstract
INTRODUCTION: Statins induce heme oxygenase-1 (HO-1) expression in vitro and in vivo. Low HO-1 expression is associated with pregnancy complications, e.g. preeclampsia and recurrent miscarriages. Here, we investigated the effects of pravastatin on HO-1 expression, placental development, and fetal survival in mice with a partial HO-1 deficiency. METHODS: At E14.5, untreated pregnant wild-type (WT, n=13-18), untreated HO-1+/- (Het, n=6-9), and Het mice treated with pravastatin (Het+Pravastatin, n=12-14) were sacrificed. Numbers of viable fetuses/resorbed concepti were recorded. Maternal livers and placentas were harvested for HO activity. Hematoxylin and eosin (H&E) and CD31 immunohistochemical staining were performed on whole placentas. RESULTS: Compared with WT, HO activity in Het livers (65±18%, P<0.001) and placentas (74±7%, P<0.001) were significantly decreased. Number of viable fetuses per dam was significantly lower in Untreated Het dams (6.0±2.2) compared with WT (9.1±1.4, P<0.01), accompanied by a higher relative risk (RR) for concepti resorption (17.1, 95% CI 4.0-73.2). In Hets treated with pravastatin, maternal liver and placental HO activity increased, approaching levels of WT controls (to 83±7% and 87±14%, respectively). The number of viable fetuses per dam increased to 7.7±2.5 with a decreased RR for concepti resorption (2.7, 95% CI 1.2-5.9). In some surviving Untreated Het placentas, there were focal losses of cellular architecture and changes suggestive of reduced blood flow in the labyrinth. These findings were absent in Het+Pravastatin placentas. DISCUSSION: Pravastatin induces maternal liver and placental HO activity, may affect placental function and improve fetal survival in the context of a partial deficiency of HO-1.
INTRODUCTION: Statins induce heme oxygenase-1 (HO-1) expression in vitro and in vivo. Low HO-1 expression is associated with pregnancy complications, e.g. preeclampsia and recurrent miscarriages. Here, we investigated the effects of pravastatin on HO-1 expression, placental development, and fetal survival in mice with a partial HO-1 deficiency. METHODS: At E14.5, untreated pregnant wild-type (WT, n=13-18), untreated HO-1+/- (Het, n=6-9), and Het mice treated with pravastatin (Het+Pravastatin, n=12-14) were sacrificed. Numbers of viable fetuses/resorbed concepti were recorded. Maternal livers and placentas were harvested for HO activity. Hematoxylin and eosin (H&E) and CD31 immunohistochemical staining were performed on whole placentas. RESULTS: Compared with WT, HO activity in Het livers (65±18%, P<0.001) and placentas (74±7%, P<0.001) were significantly decreased. Number of viable fetuses per dam was significantly lower in Untreated Het dams (6.0±2.2) compared with WT (9.1±1.4, P<0.01), accompanied by a higher relative risk (RR) for concepti resorption (17.1, 95% CI 4.0-73.2). In Hets treated with pravastatin, maternal liver and placental HO activity increased, approaching levels of WT controls (to 83±7% and 87±14%, respectively). The number of viable fetuses per dam increased to 7.7±2.5 with a decreased RR for concepti resorption (2.7, 95% CI 1.2-5.9). In some surviving Untreated Het placentas, there were focal losses of cellular architecture and changes suggestive of reduced blood flow in the labyrinth. These findings were absent in Het+Pravastatin placentas. DISCUSSION: Pravastatin induces maternal liver and placental HO activity, may affect placental function and improve fetal survival in the context of a partial deficiency of HO-1.
Authors: Shiying Hao; Jin You; Lin Chen; Hui Zhao; Yujuan Huang; Le Zheng; Lu Tian; Ivana Maric; Xin Liu; Tian Li; Ylayaly K Bianco; Virginia D Winn; Nima Aghaeepour; Brice Gaudilliere; Martin S Angst; Xin Zhou; Yu-Ming Li; Lihong Mo; Ronald J Wong; Gary M Shaw; David K Stevenson; Harvey J Cohen; Doff B Mcelhinney; Karl G Sylvester; Xuefeng B Ling Journal: PLoS One Date: 2020-03-03 Impact factor: 3.240
Authors: Christiaan M Suttorp; René E M van Rheden; Natasja W M van Dijk; Maria P A C Helmich; Anne Marie Kuijpers-Jagtman; Frank A D T G Wagener Journal: Int J Mol Sci Date: 2020-07-29 Impact factor: 5.923
Authors: Alice S Chau; Bonnie L Cole; Jason S Debley; Kabita Nanda; Aaron B I Rosen; Michael J Bamshad; Deborah A Nickerson; Troy R Torgerson; Eric J Allenspach Journal: Pediatr Rheumatol Online J Date: 2020-10-16 Impact factor: 3.413